Trace Level Quantitation of 6 Nitrosamines in Metformin API by Dynamic Headspace GC-MS/MS

Importance of the Topic

Trace levels of nitrosamine impurities in pharmaceuticals have become a major safety concern due to their genotoxic potential. Metformin, a first‐line treatment for type 2 diabetes, is consumed chronically in large populations. Regulatory agencies have defined stringent acceptable daily intake (ADI) limits for individual nitrosamines (e.g., 96 ng/day for NDMA; 26.5 ng/day for NDEA, NEIPA, NDIPA) to mitigate cancer risk. Analytical methods capable of reliably detecting nitrosamines below 30 ppb in active pharmaceutical ingredients (APIs) are essential for product safety and regulatory compliance.

Study Objectives and Overview

This application note describes the development and partial validation of a dynamic headspace GC-MS/MS method for quantifying six nitrosamines (NDMA, NDEA, NEIPA, NDIPA, NDPA, NDBA) at trace levels in Metformin API. The goal was to demonstrate improved sensitivity and robustness compared to conventional static headspace techniques.

Instrumentation Used

• Shimadzu GCMS-TQ8050 NX triple quadrupole mass spectrometer
• HS-20 dynamic headspace sampler
• 30 m × 0.25 mm I.D., 1 µm WAX ms column
• Helium carrier gas, electron ionization, argon collision gas

Methodology and Instrumentation

Standards (1 ppm) were used to optimize precursor/product ion transitions and collision energies in multiple reaction monitoring (MRM) mode. Calibration standards ranged from 0.05–0.4 ppb in headspace vials, with sample preparation involving Metformin API (100 mg) mixed with Na₂CO₃ and water. Validation followed ICH guidelines:

• Linearity: five‐point curves for most analytes (0.05–0.4 ppb) and four‐point for NDMA (0.1–0.4 ppb)
• Precision: system and LOQ‐level repeatability (n=6)
• Accuracy: spiked recovery at 0.05, 0.1, 0.3, 0.4 ppb (n=3)

Main Results and Discussion

Key validation metrics included:

• Linearity: correlation coefficients (r²) ≥ 0.988 for all six nitrosamines
• Precision at LOQ: RSD ≤ 15% (e.g., NDMA 7.5%, NDBA 10.7%)
• Limits of quantitation: dynamic headspace LOQs of 0.05 ppb (0.5 ppb w.r.t. sample) for five analytes and 0.1 ppb (1 ppb w.r.t. sample) for NDMA
• Accuracy (recovery): 80–135% for NDEA, NEIPA, NDIPA, NDPA, NDBA; NDMA accuracy not assessed due to matrix interference
• Sensitivity comparison: dynamic headspace improved LOQs by 10–20× versus static headspace

Benefits and Practical Applications of the Method

This dynamic headspace GC-MS/MS approach meets regulatory requirements for nitrosamine control in Metformin API, offering superior sensitivity and reliability. It facilitates routine QC testing, supports regulatory filings, and reduces the risk of API recalls due to nitrosamine contamination.

Future Trends and Potential Applications

Future developments may include the use of alternative salts (e.g., ammonium sulfate, sodium chloride) to minimize NDMA interference, extension of the method to finished dosage forms, and adaptation to other APIs. Ongoing advances in headspace sampling and MS technologies will further lower detection limits and streamline high-throughput analysis.

Conclusion

A dynamic headspace GC-MS/MS method with Shimadzu GCMS-TQ8050 NX and HS-20 sampler has been shown to quantify six nitrosamines at trace levels in Metformin API with excellent precision, accuracy, and sensitivity, outperforming static headspace methods and supporting stringent regulatory compliance.